comparemela.com

Latest Breaking News On - Single pill - Page 5 : comparemela.com

APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential

EQS-News: APONTIS PHARMA AG / Key word: Product Launch APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property. | April 12, 2023

Rheinland pfalzKarlheinz gastKarl heinz schleicherSven paulyManufacturing organisationContract developmentMidas pharma groupMidas pharmaSingle pillSingle pillsChief executive officerHeinz schleicherStarting materialsActive pharmaceutical ingredientsFinished productsPharma group

APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio w

EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential 12.04.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announceme.

Rheinland pfalzSven paulyKarl heinz schleicherKarlheinz gastContract developmentDistribution servicesManufacturing organisationMidas pharma groupProduct launchMidas pharmaSingle pillSingle pillsChief executive officerHeinz schleicherStarting materialsActive pharmaceutical ingredients

EQS-News: APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential Seite 1

12.04.2023 - EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential 12.04.2023 / 07:30 . Seite 1

New single pillSingle pillsSingle pillMidas pharmaApontis pharmaQs news

EQS-News: APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 Seite 1

14.02.2023 - EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 14.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the . Seite 1

New single pillSingle pillSingle pillsApontis pharmaQs news

EQS-News: APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill

EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA extends portfolio for the treatment of hypertension and hype.

Sven paulyKarlheinz gastEuropean unionSingle pillSingle pillsNew england journalChief executive officer

vimarsana © 2020. All Rights Reserved.